Share Name Share Symbol Market Type Share ISIN Share Description
Microsaic Systems Plc LSE:MSYS London Ordinary Share GB00B547ZY09 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  0.02 11.11% 0.20 57,428,075 14:23:44
Bid Price Offer Price High Price Low Price Open Price
0.19 0.21 0.21 0.18 0.18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 0.20 -2.59 -0.52 12
Last Trade Time Trade Type Trade Size Trade Price Currency
14:23:44 O 9,849,618 0.1825 GBX

Microsaic Systems (MSYS) Latest News

More Microsaic Systems News
Microsaic Systems Investors    Microsaic Systems Takeover Rumours

Microsaic Systems (MSYS) Discussions and Chat

Microsaic Systems Forums and Chat

Date Time Title Posts
28/10/202109:13Microsaic Systems - A Phoenix Rising from the Ashes196
23/8/202107:13Microsaic Systems - 20181,094
16/2/202113:37Microsaic Systems806
06/1/202119:18Microsaic - Another pump and dump disaster81
24/7/201812:24Microsaic - miniaturised chip-size scientific instruments11

Add a New Thread

Microsaic Systems (MSYS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Microsaic Systems trades in real-time

Microsaic Systems (MSYS) Top Chat Posts

Microsaic Systems Daily Update: Microsaic Systems Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker MSYS. The last closing price for Microsaic Systems was 0.18p.
Microsaic Systems Plc has a 4 week average price of 0.17p and a 12 week average price of 0.17p.
The 1 year high share price is 0.63p while the 1 year low share price is currently 0.10p.
There are currently 6,076,365,146 shares in issue and the average daily traded volume is 23,215,630 shares. The market capitalisation of Microsaic Systems Plc is £12,152,730.29.
ragnarr: More great news from DVRG - clearly going places and MSYS will are in for the ride as well. DYI
david gruen: 27 October 2021 Microsaic Systems plc ("Microsaic" or the "Company") Launch of real-time monitoring workflows and services for scaling drug manufacture Microsaic (AIM: MSYS) is pleased to announce the immediate roll-out of its compact Mass Spectrometry ("MS") technology integrated with autosampler and separation technology, wrapped in closed-loop (automated) control software, for use in the scale-up and operation of drug manufacturing. These monitoring solutions are targeted at contract research and manufacturing organisations ("CRMO"), integration partners and biopharmaceutical companies who manufacture vaccines, therapeutics for major diseases such as chronic autoimmune diseases. This offering adds turn-key services to the bioprocessing industry, using compact Microsaic technology for monitoring levels of metabolites and proteins as part of wider workflows designed to: -- increase the efficiency of biotherapeutic development and manufacture; -- reduce batch failures; and, -- create the pathway to real-time data and analytics and [potential] optimisation of biopharmaceutical manufacture. These solutions can therefore reduce manufacturing scale-up time and costs, improve quality and reduce the cost of drug manufacture, while increasing the throughput from discovery and development and the quantity of approved drugs able to reach the market in the shortest time possible. The Company's small-footprint bio-reactor monitoring technology has already demonstrated the ability to track successfully all key parameters during biomanufacture (as announced on 2 July 2021), such as feedstocks, metabolites and now additionally the target proteins (for example, complex monoclonal antibody therapeutics) in real-time. Glenn Tracey, CEO of Microsaic, commented: " The accelerated development and scale-up of COVID-19 vaccines has shown what can be achieved by biopharmaceutical manufacturing. It has also emphasised the need to find ways to develop and manufacture life-changing drugs and therapies on a large scale, both quickly and reliably. These new monitoring solutions bring potentially game-changing capabilities to monitor the material aspects of bioproduction, in real time and at the point of need, and to address these critical manufacturing needs. Additionally, Microsaic brings its expertise in workflow customisation, set up, and software control and analytics. "This extension to our range of MS equipment and solutions to cover biologic molecules, alongside other gains in detection sensitivity, immediately widens the opportunities for revenues from multiple sectors in biopharmaceuticals, healthcare and environmental industries. We expect workflow service and installations to begin in H1 2022."
daveboy19: Share price as impressed as ever !
ragnarr: Always the same theses days when results come out - unless there is something unexpectedly spectacular the traders push the price back down . These are a very solid set of results clearly showing the recovery is underway and growth is underway. Personally very happy with everything and as a LTH adding whilst price is low.
david gruen: Microsaic Systems plc 24 September 2021 24 September 2021 Microsaic Systems plc ("Microsaic" or the "Company") Microsaic sign manufacturing, supply, and service agreement to support China operations Production assembly to commence this year and on track for China medical device licence in 2022 Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments and solutions, is pleased to announce it has signed an agreement with Jiangsu Henzhihe Technologies Co. Ltd. ("HZH"), to support the Company's relationship with the Chinese distributor (the "Distributor"), with whom the Company announced a signed Heads of Terms for its micro-engineered MS technology (per the RNS dated 4 May 2021). Under the agreement ("Agreement"), HZH will provide integration and service support for Microsaic's operations in China. HZH will act as the manufacturer, integrator, and service centre in support of distribution and prospective OEM partnerships in China. HZH is a recently incorporated entity whose directors have a long history of working with MS in China and manufacturing other analytical devices, and in active pharmaceutical ingredients ("API"). Their relationships include large analytical instrumentation and pharmaceutical companies. HZH and Microsaic will collaborate with distribution partners to access and service other substantial growth opportunities in the Chinese market. Production in China of the MS hospital diagnostic monitoring equipment is expected to commence before the end of this year to support the Chinese Distributor through local production and service support, which are pre-requisites to securing a medical license . The Agreement establishes a local presence for Microsaic, accelerating the Company's growth opportunity in China. With an addressable market of 33,000 hospitals having 7.9 million beds(1) , having the ability to scale local production for MS therapeutic drug monitoring ("TDM") and maintain supply and service capability is essential. Multiple revenue streams are expected in due course, consisting of the sale of MS TDM units, franchise services and sales of reagents, in-line with Microsaic's business strategy. Once the medical license in China has been secured in 2022, HZH and the Company estimate a target rising to 100 units per annum for each therapeutic drug monitoring sector over the next two to three years, and there several sectors in this market and in other analytical sectors. HZH has confirmed it can meet the prospective demand requirements of Microsaic for China and the rest of the world. Glenn Tracey, CEO of Microsaic Systems plc, commented: "With the Company on track to secure a China medical device licence in 2022, developing the capability with local partners for mass production of Microsaic equipment in China represents a significant opportunity to reduce costs and increase available margins for these devices. This demonstrates our commitment to position our point-of-need technology in a broad range of key verticals within the human health diagnostics sector. "With a focus on commercialisation of sample-to-result platforms, and equipment with network management software capability (and later artificial intelligence ("AI") software, we look forward to providing further updates on production and distribution to the market as they arise ." Abbin Huang, MD of HZH, commented: "The Microsaic miniaturised mass spectrometers are unique and of great interest for a range of markets in China. We particularly see great potential in clinical and bioprocessing applications where real-time, point - of - need data is extremely valuable. We look forward to a long-term and close collaboration with Microsaic to serve the needs of the Chinese market ." (1) China Hospital Industry Report, 2019-2025
onehanded: Have NO investment here with MSYS, but today doing some research to see if I should. Fully invested in Deepverge. GB did confirm yesterday that MSYS is fully funded this year , which was one of my concerns of a placing soon. With that out of the way seems more attractive. Found a few good things.. MSYS is debt free Short Term Liabilities: MSYS's short term assets (£1.4M) exceed its short term liabilities (£238.3K). Long Term Liabilities: MSYS's short term assets (£1.4M) exceed its long term liabilities (£125.1K) Could be worth a small investment here.
city analyst1: Private investors would be wise to note the following: On July 08, 2021, on the IMC (Investor Meet Company) channel, Microsaic’s head honcho, Glenn Tracey, gave an unequivocally bullish response to a private investor’s question on the current share price. Using speech recognition software, and from 14:03mins to 15:40mins, I captured the entire dialogue verbatim. Here goes… PRIVATE INVESTOR “You’ve had a trail of good news recently showing a lot of traction since January. Do you think this is adequately reflected in the share price? GLENN TRACEY “I’m not surprised that question has come up. I mean, look at the news flow we’ve put out there; • We’re the first to market! • We’re the first in the world with an amazing way of getting biologics to market faster! • We’re about to get a medical licence in China and sell our product into hospitals, of which there are 33,000 in China alone! “Our news flow is month after month of really positive news.” “And yes, we’re absolutely seeing churn in the share price. But pretty much all of it is short term churn. I can say, there’s very little institutional churn.” “I think what we have to do is focus on the fundamentals of the business, which we are doing. There’s going to be more news coming out.” “I mean, this is a company that has had £30m invested in it! We’ve got a fantastic channel ahead of us. We’re bringing new products to market.” “You know, if you asked a CEO of any business, if their company was undervalued they are likely going to say yeah, of course they are. But, 0.25 of a pence, for this technology, and for this opportunity, for me is extremely undervalued. And hopefully soon, that share price will pop because the real value of this company is going to be seen.” Https://www.youtube.com/watch?v=m5B6QH5kR1Y Indiana poet, James Whitcomb Riley, once opined that, "If it looks like a duck, swims like a duck, and quacks like a duck, then it probably is a duck." In other words, MSYS is displaying all the signs of a winning technology stock on the verge of take-off. So my take on the company is simple: Against the backdrop of astonishing technological breakthroughs and commercial traction, the company is sporting a staggering risk-reward ratio and is, as a result, materially mispriced at 0.25pence per share (or £12.8m market cap). Thus, I fully concur with the CEO and expect the share price to pop sooner rather than later. AIMHO
david gruen: 06/07/2021 7:00am UK Regulatory (RNS & others) Microsaic Systems (LSE:MSYS) Intraday Stock Chart Tuesday 6 July 2021 Click Here for more Microsaic Systems Charts. TIDMMSYS RNS Number : 2415E Microsaic Systems plc 06 July 2021 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018) ("UK MAR"). 6 July 2021 Microsaic Systems plc ("Microsaic" or the "Company") Microsaic trading update for H1 2021 Unaudited revenues up 594% on H1 2020 and 52% on H1 2019, reflecting new business model Microsaic (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments is delighted to announce that a strategic change of business model early in 2021 has resulted in recovery of growth in revenues, increasing to GBP0.499m in H1 2021, significantly above H1 2020 and that of H1 2019, a pre-pandemic benchmark. First Half Highlights: -- Unaudited revenues of GBP0.499m o 594% increase over H1 2020 (GBP0.072m) and 52% over H1 2019 (GBP0.328m). -- January: transformative placing which raised GBP5.5m (gross), board changes and strategic shift away from independent development to a commercial strategy with external partners. -- Five key commercial hires to accelerate revenues on environmental detection of water contamination and in human health markets, delivering real-time on-site monitoring and data analytics with connected Internet of Things ("IoT"), AI and support services. -- March: commercial agreement with DeepVerge plc ("DeepVerge"; AIM: DVRG), through which Microsaic products and services are being deployed internationally in applications such as water monitoring of chemicals and pathogens, and in support of DeepVerge's rapidly growing Labskin division. -- May: initial shipments to a new Chinese partner to obtain a medical licence in China for real-time therapeutic monitoring of drugs with commercialisation (including service and reagents revenue sharing) expected in 2022. -- May: collaboration with Swansea University to combine real-time monitoring of environmental water using AI in determining the link between environmental chemical pollution and human health. -- June: further order from DeepVerge under the framework agreement Post Period Events: -- July: The world first demonstration of real-time monitoring of on-line production of biotherapeutic drugs such as vaccines and anti-cancer treatments using Process Analytical Technology within a Microsaic micro-engineered MS solution. Ongoing commercial developments -- Disruptive low-cost and mobile system to detect organic chemicals in water and wastewater adapted for in-field deployment. -- Detection of volatile contaminants in water, with product demonstration expected in H2 of this year. This significantly expands the reach of applications with mobile capability for environmental regulatory authorities. -- Multiple collaboration projects, including in-surgery cancer diagnostics, with the aim to secure commercial supply agreements with the potential to revolutionise surgical oncology interventions. Glenn Tracey, CEO of Microsaic Systems plc, commented: " I am thrilled to report this transformational performance for the first half of 2021, after the effects that the COVID-19 lockdown had on our customers, employees in 2020 and the financial strain this placed on the Company. The new commercial strategy of collaborating, partnering and revenue sharing has moved the Company away from equipment-only sales. We are now offering integrated real-time data analytics with AI alongside our mass spectroscopy hardware, providing complete solutions such as in-field environmental testing and on-site human diagnostics. The change of strategy and adjustment to a revenue sharing business model has demonstrated solid evidence of sales growth which is expected to continue into H2. Given the ongoing uncertainties over the effects of further waves of COVID-19 across multiple geographies, the Board remains cautious on short-term forecasting. Accordingly, we will consider whether it is appropriate to reinstate guidance to analysts after publication of the interim results, which is expected to take place during the autumn. However, prospects over the mid-term are looking more positive, with the encouraging first half results being more reflective of the Company's potential, and we look forward to our next scheduled performance update. " Related party transaction On 24 March 2021, the Company announced that it had entered into a non-exclusive Framework Services Agreement (the "Agreement") with DeepVerge. The multi-year Agreement provides for the supply by Microsaic to DeepVerge of miniaturised mass spectrometry equipment and services, across DeepVerge's sales, marketing, and distribution channels. The Agreement included an initial order of three units as well as a commitment to purchase further units in connection with the installation of pilot demonstration facilities at DeepVerge's York laboratories (together, the "Orders"). The Company has processed a further smaller purchase order from DeepVerge (the "Further Order") under the Agreement, supplying certain additional mass spectrometry equipment for quality and contamination detection in a range of markets including water and soil analysis. The value of the Further Order is approximately GBP72,000 and constitutes a related party transaction under Rule 13 of the AIM Rules. Additionally, Microsaic is loaning an additional item of equipment to DeepVerge for no consideration, to enable an early evaluation of certain technical aspects of its potential use. At the time of entering into the Agreement, the independent directors, being Glenn Tracey and Bevan Metcalf, considered, having consulted with the Company's nominated adviser, that the terms of the Agreement, were fair and reasonable insofar as the Company's shareholders are concerned. The independent directors also consider that the terms of the Further Order are consistent with the Agreement and with the terms of the initial Orders, and therefore they consider that the terms of the Further Order continue to be fair and reasonable insofar as shareholders are concerned.
ragnarr: Well using my own personal mass spectrometry technology I detect very little BB activity ratio here relative to share price upward movement.Slightly surprising :-))
pass the dutchy: ANA will be the UK’s leading cannabis producer (200 TONS per year that’s worth £400m) Share price 1.45p Only £8m mkt cap Fastest growing sector worldwide Will have first mover advantage in UK Same growers as GW Pharma (just got sold for £5b) 4 biggest shareholders hold over 50% BOD own 30% Massively undervalued Near term multi bagger on license approval Partners with leading prof , scientists etc Primed for a RTO/ main listing (price driver) Under the radar (most chased MXC,CBX) Looking to bring a product to market Off take agreement in place already Will be producing 200 TONS per year (200,000 kilos) Has the most land out of every UK cannabis co (40 hectares) Fully funded for phase 1 UK medical cannabis growing 20% month Only 584m shares in issue Hardly any available in open market Will apply for a commercial license too hTTps://businesscann.com/work-on-12m-medicinal-cannabis-cultivation-facility-held-up-by-covid-19-uk-travel-ban/ hTTps://anandadevelopments.com/tiamat-agriculture-ltd/ Targets and price movers :- 5p+ on license (imminent) 10p+ RTO/Main Listing 20p+ commercial license £1+ when producing 200 TONS per year Well worth taking a position whilst it’s still on the ground floor imo.
Microsaic Systems share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Microsaic ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 15:37:47